MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599096 | Name: Deparon

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deparon is a tricyclic antidepressant that can also serve as a new potential antibacterial agent.

Chemical Structure

Deparon
Deparon
CAS#18059-99-9

Theoretical Analysis

MedKoo Cat#: 599096

Name: Deparon

CAS#: 18059-99-9

Chemical Formula: C18H19ClN2O

Exact Mass: 314.1186

Molecular Weight: 314.81

Elemental Analysis: C, 68.68; H, 6.08; Cl, 11.26; N, 8.90; O, 5.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Deparon; LM 2909; LM-2909; LM2909; Demexiptiline hydrochloride;
IUPAC/Chemical Name
5H-dibenzo[a,d][7]annulen-5-one O-(2-(methylamino)ethyl) oxime hydrochloride
InChi Key
MZTHMUGFMPRTIK-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H18N2O.ClH/c1-19-12-13-21-20-18-16-8-4-2-6-14(16)10-11-15-7-3-5-9-17(15)18;/h2-11,19H,12-13H2,1H3;1H
SMILES Code
CNCCO/N=C1C2=CC=CC=C2C=CC3=CC=CC=C\13.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 314.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. PubMed PMID: 8918275. 2: Tomson D, Lessert C, Luthi I, Mazzolai L, Depairon M. [Lymphatic vascular pathologies: contribution of lympho-fluoroscopy]. Rev Med Suisse. 2015 Feb 4;11(460):362-5. French. PubMed PMID: 25854047. 3: Yerly P, Marquès-Vidal P, Owlya R, Eeckhout E, Kappenberger L, Darioli R, Depairon M. The atherosclerosis burden score (ABS): a convenient ultrasound-based score of peripheral atherosclerosis for coronary artery disease prediction. J Cardiovasc Transl Res. 2015 Mar;8(2):138-47. doi: 10.1007/s12265-015-9617-5. Epub 2015 Mar 14. PubMed PMID: 25771948. 4: Calanca L, Alatri A, Depairon M, Engelberger RP, Mazzolai L. [Non atherosclerotic arterial disease of lower limbs]. Rev Med Suisse. 2015 Feb 4;11(460):352, 354-6. French. PubMed PMID: 25854045. 5: Krieger Caroline, Roessingh Ade B, Depairon M, El Ezzi O, Hohlfeld J, Raffoul W, Qanadli SD, Mazzolai L. [Vascular anomalies]. Rev Med Suisse. 2015 Feb 4;11(460):357-61. French. PubMed PMID: 25854046. 6: Calanca L, Depairon M, Tribout B, Aebischer N, Burnier M, Fellmann F, Lazor R, Mazzolai L. [Rare vascular diseases]. Rev Med Suisse. 2014 Feb 5;10(416):347-50, 352. French. PubMed PMID: 24624629. 7: Glauser F, Mazzolai L, Darioli R, Depairon M. Interaction between widening of diameter of abdominal aorta and cardiovascular risk factors and atherosclerosis burden. Intern Emerg Med. 2014 Jun;9(4):411-7. doi: 10.1007/s11739-013-0941-y. Epub 2013 Apr 9. PubMed PMID: 23568317. 8: Erdmann A, Alatri A, Engelberger RP, Depairon M, Calanca L, Mazzolai L. [Suspicion of lower limb deep vein thrombosis: update on diagnosis and treatment]. Rev Med Suisse. 2015 Feb 4;11(460):337-41. French. Erratum in: Rev Med Suisse. 2015 Feb 18;11(462):475. PubMed PMID: 25854042. 9: Zingg S, Collet TH, Locatelli I, Nanchen D, Depairon M, Bovet P, Cornuz J, Rodondi N. Associations Between Cardiovascular Risk Factors, Inflammation, and Progression of Carotid Atherosclerosis Among Smokers. Nicotine Tob Res. 2016 Jun;18(6):1533-8. doi: 10.1093/ntr/ntv255. Epub 2015 Nov 16. PubMed PMID: 26574552. 10: Tomson D, Lessert C, Klumbach D, Mazzolai L, Depairon M. [Lymphatic disorders and prevention of their complications]. Rev Med Suisse. 2012 Feb 8;8(327):315-6, 318-9. French. PubMed PMID: 22393652. 11: Krähenbühl SM, Depairon M, Faure M, Vietti Violi N, Applegate LA, Raffoul W. Sildenafil as a therapeutic option for digital ischemic ulceration: case report. J Hand Surg Am. 2015 May;40(5):890-3. doi: 10.1016/j.jhsa.2015.01.041. Epub 2015 Mar 25. PubMed PMID: 25817752. 12: Glauser F, Codreanu A, Tribout B, Mazzolai L, Depairon M. [Prevention of chronic venous disease: which advice for our patients?]. Rev Med Suisse. 2012 Feb 8;8(327):306-8, 310. French. PubMed PMID: 22393650. 13: Depairon M, Vuagnat H. [Ulcer management--a multidisciplinary approach]. Praxis (Bern 1994). 2008 Feb 20;97(4):165. French. PubMed PMID: 18548794. 14: Marques-Vidal P, Imsand D, Kayoumi A, Kern P, Mazzolai L, Depairon M. [Quality of life in patients traited for primary superficial venous insufficiency]. Praxis (Bern 1994). 2012 May 9;101(10):645-50. doi: 10.1024/1661-8157/a000938. French. PubMed PMID: 22565555. 15: Depairon M, Pittet L, Paillex R, Klumbach D, Mazzolai L. [To live with lymphedema: present and future]. Rev Med Suisse. 2009 Feb 4;5(189):299-302. French. PubMed PMID: 19271645. 16: Depairon M, Hayoz D, Darioli R. [Early detection of atherosclerosis]. Rev Med Suisse. 2006 Feb 1;2(51):330-2, 335-6. Review. French. PubMed PMID: 16512004. 17: Fumeaux J, Depairon M, Mazzolai L. [Vascular diseases: what screening could be done in the office?]. Rev Med Suisse. 2008 Feb 6;4(143):336-8, 340-2. Review. French. PubMed PMID: 18386669. 18: Depairon M. [Anatomy and physiopathology of venous system]. Praxis (Bern 1994). 2006 Mar 22;95(12):451-3. Review. French. PubMed PMID: 16602218. 19: Codreanu A, Calanca L, Glauser F, Corpataux JM, Qanadli S, Mazzolai L, Depairon M. [Vascular follow up in patients suffering from peripheral arterial disease and undergoing revascularization]. Rev Med Suisse. 2012 Feb 8;8(327):324-7. French. PubMed PMID: 22393654. 20: Depairon M, Lapière CM. [Prognosis and prevention of white atrophy]. Phlebologie. 1986 Jul-Sep;39(3):617-20. French. PubMed PMID: 3786435.